Evidence map›Paper›PMID 33688262›Full record

ArticleCancer management and research2021

Combination of

Ping Li, Chang Liu, Shuang Wu, Lin Deng, Guangyuan Zhang, Xin Cai, Silong Hu, Jingyi Cheng, Xiaoping Xu, Bin Wu and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Development and Characterization ofInternational journal of molecular sciences · 2023
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 1 country.

Ping Li *Department of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, People's Republic of China.
Chang Liu *Department of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Shuang WuShanghai Key Laboratory of Radiation Oncology, Shanghai, People's Republic of China.
Lin DengShanghai Key Laboratory of Radiation Oncology, Shanghai, People's Republic of China.
Guangyuan ZhangShanghai Key Laboratory of Radiation Oncology, Shanghai, People's Republic of China.
Xin CaiDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, People's Republic of China.
Silong HuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Jingyi ChengShanghai Key Laboratory of Radiation Oncology, Shanghai, People's Republic of China.
Xiaoping XuDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.ORCID 0000-0001-9656-6233
Bin WuShanghai Key Laboratory of Radiation Oncology, Shanghai, People's Republic of China.
Xiaomao GuoShanghai Key Laboratory of Radiation Oncology, Shanghai, People's Republic of China.
Yingjian ZhangDepartment of Nuclear Medicine, Fudan University Shanghai Cancer Center, Shanghai, People's Republic of China.
Shen FuKey Laboratory of Nuclear Physics and Ion-Beam Application (MOE), Fudan University, Shanghai, People's Republic of China.
Qing ZhangDepartment of Radiation Oncology, Shanghai Proton and Heavy Ion Center, Shanghai, People's Republic of China.
Center for High Pressure Science & Technology Advanced Research · CNFudan University · CNFudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe purpose of this study was to assess the potential of PATIENTS AND

methodsWe prospectively registered 26 patients with localized prostate cancer treated with CIRT. All patients underwent

resultsThe median follow up time was 38.3months. The TBR was significantly decreased (

conclusionOur preliminary data indicate that the changes of TBR and ADC

Indexed as

carbon ion radiotherapyDWIprostate cancerPSMA

Identifiers

PMID33688262
PMCPMC7937376
OpenAlexW3133815284

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.